Amylyx Pharmaceuticals, Inc. Common Stock (AMLX) is a publicly traded Healthcare sector company. As of July 14, 2026, AMLX trades at $17.40 with a market cap of $1.98B and a P/E ratio of -11.17. AMLX moved -2.14% today. Year to date, AMLX is +45.08%; over the trailing twelve months it is +126.69%. Its 52-week range spans $2.60 to $19.15. Analyst consensus is strong buy with an average price target of $26.29. Rallies surfaces AMLX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for AMLX, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $17.40 |
| Market Cap | $1.98B |
| P/E Ratio | -11.17 |
| EPS | $-1.53 |
| Dividend Yield | 0.42% |
| 52-Week High | $19.15 |
| 52-Week Low | $2.60 |
| Volume | 1.24M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-144.74M |
| Gross Margin | 0.00% |
8 analysts cover AMLX: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $26.29.